INBRX-101 is a recombinant human AAT-Fc fusion protein designed to replace the enzyme that is deficient in AATD and offer less frequent dosing than current therapies for the disease, based on ...

Methods The study population included 21 severe AATD (ZZ), 22 moderate AATD (MZ) and 23 non-AATD (MM) individuals, further categorised as healthy, unobstructed current smokers or patients with chronic ...

Mereo BioPharma targets osteogenesis imperfecta market growth with setrusumab. Discover why MREO stock is well-positioned for ...

Korro Bio has secured approvals in Australia to commence the Phase I/IIa trial of KRRO-110, aimed at treating AATD.

There are an estimated 200,000 individuals living with AATD in the US and Europe with this genetic form of the disease. M-ATT levels were below the limit of detection at baseline, but rose to ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...

Cholesterol Is Not the Only Lipid Involved in Trans Fat-Driven Cardiovascular Disease Nov. 18, 2024 — Salk scientists have tracked the flow of trans fats using mouse models to describe the ...

Healthcare providers use many terms to describe the progress of a cancer or its response to treatment. Progressive disease describes cancer that is growing, progressing, or worsening. There are many ...